anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Propafenone is highly metabolized by the liver. Severe liver dysfunction increases the bioavailability of propafenone to approximately 70% compared with 3% to 40% in patients with normal liver function when given propafenone immediate release tablets. In 8 patients with moderate to severe liver disease administered propafenone immediate release tablets, the mean half-life was approximately 9 hours. No trials have compared bioavailability of propafenone from propafenone ER capsules in patients with normal and impaired hepatic function. Increased bioavailability of propafenone in these patients may result in excessive accumulation. Carefully monitor patients with impaired hepatic function for excessive pharmacological effects [see OVERDOSAGE (10)].
This is a phase Ib, open-label, single-arm study in newly diagnosed patients with extensive stage SCLC, to test the safety of the adaptive addition of SBRT to combination therapy with durvalumab, platinum, and etoposide. Approximately 50 patients with ES-SCLC will be enrolled in this study in order to identify 20 patients with platinum refractory disease who do not show evidence of early response to chemoimmunotherapy. Eligible patients will complete 2 cycles of study treatment with durvalumab, platinum (cisplatin or carboplatin per investigator choice), and etoposide. Patients will then undergo standard of care restaging imaging. Those patients who have a partial or complete response will continue with combination systemic therapy, without additional intervention.

In patients with less than a partial response (stable disease or progressive disease), SBRT will be given prior to cycle 3 of systemic therapy. The radiotherapy will be given in 5 fractions of 6 Gy to the primary tumor site. See study schema. Patients who undergo SBRT will resume systemic therapy within 2 weeks of completing SBRT and the interval between cycle 2 and cycle 3 should not exceed 6 weeks. Subsequent restaging imaging will continue as per standard of care. All patients will continue maintenance therapy with durvalumab until confirmed progressive disease.
Pediatric patients who are undergoing a surgical procedure with anesthesia. Patients will have type 1 diabetes and be wearing a continuous glucose monitor as part of routine care.
During a medical intervention, such as angiography, an X-ray examination apparatus (e.g. mounted on a C-arm) generates a large number of interventional imaging frames as its operation progresses. This information contains a sequence of frames that may be useful for improving the interventional medical report. These sequences will contain sequences containing similar clinical information, although the frames may be considered redundant and not suitable for inclusion in a medical report. Aspects detailed herein enable non-redundant sequences and/or frames to be selected during an intervention based on contextual information obtained from an image sequence and/or other medical instrument. In this way, the redundancy inherent in the original frame sequence can be removed, leaving a set of candidate sequences ready for insertion into a multimedia medical report or a file medical report.
OBJECTIVE: To study the changes of lung function, pathophysiology, inflammatory cytokines and related inflammatory responses in COPD mouse model, and to analyze the role of sRAGE in the pathogenesis of COPD induced by cigarette smoke (CS) exposure in mice.
METHODS: 24 healthy male C57BL/6J mice aged 6 to 8 weeks were randomly divided into Smoke-Exposed (SE) group and Control group. The mice in SE group were exposed to 7 time points at 3, 7, 15, 30, 60, 90 and 120 days, while mice in control group were exposed to fresh room air, with 3 mice in each group. Lung function of mice was detected at different exposure time points, and the lung tissue sections were stained with HE to observe the lung histopathological changes of mice in each group, and the lung tissue morphological quantitative analysis was performed to evaluate the degree of emphysema. The content of inflammatory cytokines including IL-1β, IL-6 and TNF-α in the supernatant of BALF was detected by ELISA to evaluate the pulmonary inflammation of mice. The expression of sRAGE in BALF supernatant was detected by ELISA. BALF cell precipitates were classified and counted under light microscope.
RESULTS: After 90 days of exposure to cigarette smoke, the lung function of mice was significantly reduced, emphysema appeared significantly, and the expression of inflammatory cells and inflammatory cytokines in BALF was significantly increased (all P<0.05). sRAGE increased significantly in the early stage of CS exposure (7-15 days) compared with the control group, and the number of macrophages and levels of inflammatory cytokines in BALF also increased temporarily (P<0.05). With the gradual exposure of CS, sRAGE expression gradually decreased, and was significantly reduced after COPD formation compared with the control group.
CONCLUSION: In the process of the occurrence and development of chronic obstructive pulmonary disease induced by cigarette smoke exposure, the level of sRAGE in bronchoalveolar lavage fluid showed a dynamic change of first increase and then decrease. The expression of sRAGE increased in the early stage of smoke exposure and played a transient pro-inflammatory role. With long-term exposure to cigarette smoke, the inflammatory response is gradually aggravated in lung, and the expression of sRAGE is significantly decreased, and its reduction degree is closely related to the degree of reduced lung function and inflammation.
This comprehensive review delves into cancer's complexity, focusing on adhesion, metastasis, and inhibition. It explores the pivotal role of these factors in disease progression and therapeutic strategies. This review covers cancer cell migration, invasion, and colonization of distant organs, emphasizing the significance of cell adhesion and the intricate metastasis process. Inhibition approaches targeting adhesion molecules, such as integrins and cadherins, are discussed. Overall, this review contributes significantly to advancing cancer research and developing targeted therapies, holding promise for improving patient outcomes worldwide. Exploring different inhibition strategies revealed promising therapeutic targets to alleviate adhesion and metastasis of cancer cells. The effectiveness of integrin-blocking antibodies, small molecule inhibitors targeting Focal adhesion kinase (FAK) and the Transforming Growth Factor β (TGF-β) pathway, and combination therapies underscores their potential to disrupt focal adhesions and control epithelial-mesenchymal transition processes. The identification of as FAK, Src, β-catenin and SMAD4 offers valuable starting points for further research and the development of targeted therapies. The complex interrelationships between adhesion and metastatic signaling networks will be relevant to the development of new treatment approaches.
Renal manifestations of chronic hyperoxaluria include nephrolithiasis and, when extreme, interstitial scarring and progressive loss of function. The clinical outcome can be dismal. Although primary hyperoxaluria is relatively rare, hyperoxaluria secondary to gastrointestinal malabsorption is not. Furthermore, the formation of calcium oxalate kidney stones is extremely common, and evidence suggests that minimal, perhaps transient elevations in urinary oxalate concentration may be an important factor in at least a subgroup of these patients with "idiopathic" calcium oxalate urolithiasis. In the case of enteric hyperoxaluria the pathogenic role of oxalate is clear, and renal scarring is commonly observed as a consequence of oxalate exposure and calcium oxalate crystal deposition, in addition to stones. Unfortunately, few satisfactory specific treatments for enteric hyperoxaluria are available. Typical strategies include dietary restriction of oxalate to limit its delivery to the colon; low fat diets to limit malabsorption and distal colonic effects of fatty acids and bile acids; oral calcium to bind oxalate; and bile acid sequestrants like cholestyramine. In its entirety, this regimen is quite rigorous for patients, and even if compliance is achieved the therapy is not always effective. Previous studies have shown that components of the endogenous digestive microflora can utilize oxalate, potentially limiting its absorption from the intestinal lumen. A recent preliminary study demonstrated that a preparation of lactic acid bacteria degraded oxalate in vitro and reduced urinary oxalate excretion when given by mouth. We have recently demonstrated that the same preparation of lactic acid bacilli (Oxadrop) can reduce urinary oxalate excretion in patients with enteric hyperoxaluria. In the current proposal, in a placebo-controlled trial we will determine the effectiveness of this and another probiotic preparation (Agri-King Synbiotic) \[AKSB\] for the treatment of hyperoxaluria in patients with mild hyperoxaluria, as well as enteric hyperoxaluria.

Specific Aims are: 1) Determine the effect of two probiotic preparations (AKSB and Oxadrop on urinary oxalate excretion in a well-defined group of patients with enteric hyperoxaluria; and 2) Determine the effect of two probiotic preparations (AKSB and Oxadrop) on urinary oxalate excretion in a well-defined group of patients with idiopathic calcium oxalate urolithiasis and mild hyperoxaluria. If results are positive, treatment for calcium oxalate kidney stones could be revolutionized.
The inflammatory bowel disease is a chronic bowel disorder; it can involve the whole gastrointestinal tract, but its localization in the ileum or colon is most common. The reference standard for the diagnosis of inflammatory bowel disease is ileocolonoscopy with histologic assessment. Dan Carter, Lior H. Katz, Eytan Bardan, Eti Salomon, Shulamit Goldstein, Shomron Ben Horin, Uri Kopylov, and Rami Eliakim The reference standard for the detection of any complications is surgery. However, imaging techniques have an important role both in the detection/localization of C D and in the followup of C D patients. In the last few years, the technical development of ultrasound equipment, the advent of new technologies such as elastography and mostly the increased expertise of sonographers have boosted the role of bowel ultrasound in assessment of the gastrointestinal tract. In fact, bowel ultrasound is particularly attractive thanks to its widespread availability, non-invasiveness, low cost and good reproducibility, as it can be easily repeated during follow-up Clara Benedetta Conti , Mariangela Giunta , Daniele Gridavilla , Dario Conte , Mirella Fraquelli . Bowel ultrasound has become the first-line imaging technique for patients with suspected C rohn's disease because it is cheap ,less radiation effect ,it can be done more than one time for follow up these patient . Some signs, for example, bowel loop elasticity (i.e., the capability of the bowel wall to collapse on the bowel lumen and return to the original size and shape after manual compression and decompression) and compressibility at probe contact and peristalsis (usually impaired), are not specific, whereas other signs, such as the characteristics of the bowel wall, are more specific. Among the latter, the most important sign is bowel wall thickening (BWT) . Also important are bowel wall echo pattern characteristics (BWP) , the presence of any margin irregularity and the grade of vascularity at echo color Doppler or power Doppler . Other yet less frequent signs are the luminal alterations, such as the distension or any luminal stenosis. Other possible findings outside the bowel loop are mesenteric hypertrophy , enlarged mesenteric lymph nodes and free fluid in the abdominal cavity or among the bowel loops .
The present invention relates to a pharmaceutical composition comprising piperonylic acid as an effective ingredient for anti-aging or regenerating the skin. A composition according to the present invention utilizes piperonylic acid that various plant species naturally contain therein and thus does not cause side effects. Piperonylic acid activates signals associated with cell survival, growth, and proliferation to exhibit the effect of increasing the resistance and survival of skin cells against external stimuli and enhancing the regeneration of the skin damaged due to external stimuli or senescence. In addition, piperonylic acid of the present invention has a similar function to EGF, but is stable and small in size in contrast to EGF. Thus, piperonylic acid of the present invention has the advantage of being able to easily move to the skin basal layer across the skin barrier and perform its function. Piperonylic acid of the present invention is expected to find applications in various fields including medicines, quasi-drugs, cosmetics, cosmetic substances, functional biomaterials, and functional food materials.
Sirtuin 1 (SIRT1) participates in the initiation and evolution of hepatocellular carcinoma (HCC). However, the specific mechanism of SIRT1 in HCC remains unclear. The mRNA expression of miR-29a in HCC were identified by qRT-PCR. miR-29a mimic and inhibitor were employed. The alteration of biological behavior was evaluated by Cell Counting Kit-8 (CCK8), clone formation, transwell and wound-healing assay. SIRT1 was verified to be a target gene which directly regulated by miR-29a. Luciferase reporter assay and co-IP were employed to evaluate the direct binding of miR-29a and SIRT1. Animal model was used to evaluate its function on tumor growth and metastasis in vivo. The relationship between miR-29a/SIRT1 and prognosis of HCC patients was analyzed. SIRT1 overexpression accompanied by low expression of miR-29a were detected in HCC which was negatively correlated, and associated with overall survival, vascular invasion and TNM stage. Up-regulation of miR-29a suppressed cell growth and motility. Deprivation of miR-29a expression led to opposite effect. The direct binding of miR-29a to SIRT1 was confirmed by luciferase reporter assay and co-IP. miR-29a repressed SIRT1, DKK2 and β-catenin, but their expression was obviously elevated by miR-29a inhibitor. Animal model suggested miR-29a could reduce the expression of SIRT1, thereby inhibiting HCC growth and metastasis by inactivating Wnt/β-catenin pathway. Low expression of miR-29a and high expression of SIRT1 predicted shorter survival time in HCC patients. miR-29a had the function of tumor suppressor which directly inhibited oncogenic SIRT1. The loss of miR-29a led to up-regulation of SIRT1, aggravate malignant transformation and poor prognosis of HCC.
Tailored ketogenic diet. Participants will be allowed to chose their meals as long as they consume less than 50gr of carbohydrates per day.
Subjects will receive AK112 Plus Pemetrexed and Carboplatin via intravenous infusion (IV) Q3W, up to 4 cycles. Afterward, AK112 Plus Pemetrexed will be used for maintenance treatment (administered on Day 1 of each cycle, Q3W) up to 2 years.
FIELD: pharmacy. SUBSTANCE: invention relates to construction of lipid agent which is equivalent to cationic liposome but less toxic and containing lipid or its analog as a component of this agent. Invention relates to compounds of the general formula (I)   where R 1  and R 2  are distinct and each means a group -O-Y or a group -A-(CH 2 ) n -E where n is a whole number from 2 to 4; E means pyrrolidine-, piperidine- or morpholine-group or others, or E means a group   where R 3  and R 4  are similar or distinct and each means hydrogen atom, lower-(C 1 -C 4 )-alkyl, hydroxy-lower-(C 1 -C 4 )- -alkyl; A means groups of formulas:   where R and Y are similar and each means oleyl or oleoyl or palmitoyl at condition that when n = 1 then A can not be a group   and  . Invention relates to also an agent for delivery of physiologically active substance containing phospholipid and modifying component, and a pharmaceutical composition containing an agent for delivery of physiologically active substance, physiologically active substance and an inert diluting agent. EFFECT: improved properties of composition. 12 cl, 2 tbl, 50 ex
PCT No. PCT/DE94/01394 Sec. 371 Date Jul. 18, 1996 Sec. 102(e) Date Jul. 18, 1996 PCT Filed Nov. 21, 1994 PCT Pub. No. WO95/20048 PCT Pub. Date Jul. 27, 1995The invention relates to a process for producing outer membrane proteins of gram-negative bacteria by gram-positive host cells. To this end, a gene structure containing a gene coded for an outer membrane protein is constructed; in front of this gene there is a pro-gene sequence which codes for a propeptide of an export protein of a gram-positive bacterium. In front of the pro-gene sequence there is a pre-gene sequence which codes for a signal peptide of an export protein of a gram-positive bacterium. After the cloning of a gene structure thus constructed into a vector and transformation into a gram-positive bacterium, the outer membrane protein is expressed with a signal peptide and propeptide, transported through the membrane of the gram-positive host cell and released into the test of the culture.
PURPOSE: To evaluate the structural, microvascular, and functional progression of normal tension glaucoma (NTG) with or without high myopia by examining longitudinal changes in optical coherence tomography angiography (OCTA) and visual field (VF) parameters.
METHODS: We evaluated 61 NTG eyes and classified 25 of the eyes with axial lengths (ALs) of ≥26 mm as highly myopic. We assessed the rate of change in OCTA parameters, namely radial peripapillary capillary (RPC) vessel density (VD), parafovea VD, deep parafovea VD, retinal nerve fibre layer (RNFL) thickness, and ganglion cell complex thickness. We evaluated the correlation of the rate of change in OCTA parameters with VF loss and AL.
RESULTS: Among the 61 NTG eyes, rates of loss of RPC VD, parafovea VD, deep parafovea VD, and RNFL thickness were significantly different from zero despite the nonsignificant rate of change in VF mean deviation (MD). Changes in these OCTA parameters did not differ significantly in highly myopic NTG eyes. The rate of change in VF MD was significantly correlated with the rate of change in parafovea VD in highly myopic and non-highly myopic NTG eyes. In highly myopic NTG eyes, AL was negatively correlated with the rates of loss of RNFL thickness, VF MD, and VF PSD.
CONCLUSION: NTG eyes with a relatively stable VF exhibited loss of VD and RNFL thickness. VF progression in NTG was correlated with decreasing parafovea VD, indicating a structure-function correlation. Greater AL may indicate faster VF loss and RNFL thinning in highly myopic NTG eyes.
PURPOSE:A safe, effective agent for lowering intraocular pressure, containing a naphthylmethanol derivative or a salt thereof as an active ingredient. CONSTITUTION:An agent for lowering intraocular pressure containing a compound shown by the formula or a salt thereof. The compound has lowering action on mammalian intraocular pressure with a low concentration, low toxicity and exerts no bad influence on pupillary diameter so it is effective as a remedy for glaucoma, etc. Eye drop, eye ointment, etc., may be cited as a dosage form and the compound is pharmaceutically manufactured so as to be administered locally. In the case of dye drop, 0.0001-1.0wt%, preferably 0.001-0.1wt% active ingredient is used and pharmaceutically manufactured. As administration method, the agent is applied once - four times a day and one - several drops are administered per time. Also in the case of eye ointment, 0.0001-1.0wt%, preferably 0.001-0.1wt% main drug is mixed and pharmaceutically manufactured and the agent is administered one - four times a day.
The retrospective cohort consists of about 839 kidney transplant recipients from Nanfang Hospital. These patients used tacrolimus as immunosuppressive drug for preventing the rejection.The side effects (acute rejection, nephrotoxicity and neurotoxicity) will be recorded.
BACKGROUND: Macrophages are involved in kidney transplants. The aim of the study was to investigate if changes exist in the levels of glomerular macrophage index (GMI) between two consecutive kidney transplant biopsies, and if so to determine their potential impact on graft survival.
METHODS: Two consecutive biopsies were performed on the same renal graft in 623 patients. GMI was categorized into three GMI classes: ≤1.8 Low, 1.9-4.5 Medium, and ≥4.6 High. This division yielded nine possible switches between the first and second biopsies (Low-Low, Low-Medium, etc.). Cox-regressions were used and hazard ratios (HR) with 95% confidence interval (CI) are presented.
RESULTS: The worst graft survival was observed in the High-High group, and the best graft survival was observed in the Low-Low and High-Low groups. Compared to the High-High group, a reduction of risk was observed in nearly all other decreasing groups (reductions between 65% and 80% of graft loss). After adjustment for covariates, the risk for graft-loss was lower in the Low-Low (HR = 0.24, CI 0.13-0.46), Low-Medium (HR = 0.25, CI 0.11-0.55), Medium-Low (HR = 0.29, CI 0.11-0.77), and the High-Low GMI (HR = 0.31, CI 0.10-0.98) groups compared to the High-High group as the reference.
CONCLUSIONS: GMI may change dynamically, and the latest finding is of most prognostic importance. GMI should be considered in all evaluations of biopsy findings since high or increasing GMI levels are associated with shorter graft survival. Future studies need to consider therapeutic strategies to lower or maintain a low GMI. A high GMI besides a vague histological finding should be considered as a warning sign requiring more frequent clinical follow up.
PURPOSE: A composition and a cosmetic composition containing an Inulae Radix extract are provided to induce renal cancer cell apoptosis and to treat renal cancer. CONSTITUTION: A composition for treating renal cancer contains an Inulae Radix extract as an active ingredient. The extract is prepared using ethanol at 50 deg. C. for 24 hours, and dried and concentrated at 45 deg. C. The composition contains a pharmaceutically acceptable carrier or diluents. The renal cancer is kidney cell cancer. [Reference numerals] (AA) Relative cellular viability
Products for internal or external use contg., as active ingredients, the milk contg. the eggs from a mollusc, esp. an oyster taken just prior to deposition of the eggs. The products may be in the form of creams, emulsions, or solutions for external use, the active ingredient being lyophilised and mixed with appropriate carriers. They may also be given orally or by injection. The milk containing the eggs is preferably taken 2 to 5 days before deposition, this time being measured by comparison with a colony of molluscs in a neighbouring, but slightly more favourable position. The product has a cicatrising, revitalising and rejuvenating effect.
PROBLEM TO BE SOLVED: To use a specific hydroxystilbene compound as a deodorizing agent in a cosmetic composition for topical application to persons, wherein the hydroxystilbene compound is contained in an amount sufficient and preferable to be taken in the composition, is soluble in water and prevents the generation of body smells. SOLUTION: At least one compound of the formula [A is H, OR2 group (R1 and R2 are each H, a 1-4C alkyl or the like); R4 and R5 are each H or hydroxy) as a deodorizing agent in a cosmetic composition. The compound of the formula is preferably 3.5-dihydroxystilbene (pinosylvin), which is preferably synthesized. The pinosylvin is preferably derived from a plant extract containing the pinosylvin. The plant extract is preferably obtained from Pinus in Pinacea, especially Pinus montana mill, Pinus sylvestris L, or the like. The compound of the formula is preferably 3-hydroxystilbene.